Cargando…

Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study

BACKGROUND: There is a scarcity of data regarding the effect of Type 2 diabetes mellitus (T2DM) and associated comorbidities on the clinical presentation and outcome of symptomatic patients with COVID-19 infection in comparison with non-diabetic patients. AIM OF THE STUDY: We described and compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Soliman, Ashraf, Prabhakaran Nair, Arun, Al Masalamani, Muna S., De Sanctis, Vincenzo, Abu Khattab, Mohamad A., Alsaud, Arwa E., Sasi, Sreethish, Ali, Elrazi A., Hassan, Ola A., Iqbal, Fatima M., Nashwan, Abdulqadir J., Fahad, Jesin, El Madhoun, Ihab, Yassin, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716959/
https://www.ncbi.nlm.nih.gov/pubmed/32921708
http://dx.doi.org/10.23750/abm.v91i3.10214
_version_ 1783619262340923392
author Soliman, Ashraf
Prabhakaran Nair, Arun
Al Masalamani, Muna S.
De Sanctis, Vincenzo
Abu Khattab, Mohamad A.
Alsaud, Arwa E.
Sasi, Sreethish
Ali, Elrazi A.
Hassan, Ola A.
Iqbal, Fatima M.
Nashwan, Abdulqadir J.
Fahad, Jesin
El Madhoun, Ihab
Yassin, Mohamed
author_facet Soliman, Ashraf
Prabhakaran Nair, Arun
Al Masalamani, Muna S.
De Sanctis, Vincenzo
Abu Khattab, Mohamad A.
Alsaud, Arwa E.
Sasi, Sreethish
Ali, Elrazi A.
Hassan, Ola A.
Iqbal, Fatima M.
Nashwan, Abdulqadir J.
Fahad, Jesin
El Madhoun, Ihab
Yassin, Mohamed
author_sort Soliman, Ashraf
collection PubMed
description BACKGROUND: There is a scarcity of data regarding the effect of Type 2 diabetes mellitus (T2DM) and associated comorbidities on the clinical presentation and outcome of symptomatic patients with COVID-19 infection in comparison with non-diabetic patients. AIM OF THE STUDY: We described and compared the clinical presentation and radiological and hematological data of a cohort of symptomatic COVID19 positive T2DM diabetic patients (n = 59) versus another cohort of non-diabetic symptomatic COVID19 positive patients (n =244) diagnosed at the same time from January 2020 to May 2020. Associated comorbidities were assessed, and the Charlson Comorbidity Index was calculated. The outcomes including duration of hospitalization, duration of Intensive Care Unit (ICU) stay, duration of mechanical ventilation, and duration of O2 supplementation were assessed. RESULTS: Prevalence of T2DM in symptomatic COVID19 positive patients was 59/303 (=19.5%). Diabetic patients had higher prevalence of hypertension, chronic kidney disease (CKD) and cardiac dysfunction [coronary heart disease (CHD)], and congestive heart failure (CHF). Charlson Comorbidity score was significantly higher in the T2DM patients (2.4± 1.6) versus the non-diabetic patients (0.28 ± 0.8; p: < 0.001). Clinically and radiologically, T2DM patients had significantly higher percentage of pneumonia, severe pneumonia and ARDS versus the non-diabetic patients. Hematologically, diabetic patients had significantly higher C-reactive protein (CRP), higher absolute neutrophilic count (ANC) and lower counts of lymphocytes and eosinophils compared to non-diabetic patients. They had significantly higher systolic and diastolic blood pressures, longer duration of hospitalization, ICU stay, mechanical ventilation and oxygen therapy. CRP was correlated significantly with the duration of stay in the ICU and the duration for oxygen supplementation (r = 0.37 and 0.42 respectively; p: <0.01). CONCLUSIONS: T2DM patients showed higher inflammatory response to COVID 19 with higher absolute neutrophilic count (ANC) and CRP with lower lymphocytic and eosinophilic counts. Diabetic patients had more comorbidities and more aggressive course of the disease with higher rate of ICU admission and longer need for hospitalization and oxygen use.
format Online
Article
Text
id pubmed-7716959
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Mattioli 1885
record_format MEDLINE/PubMed
spelling pubmed-77169592020-12-07 Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study Soliman, Ashraf Prabhakaran Nair, Arun Al Masalamani, Muna S. De Sanctis, Vincenzo Abu Khattab, Mohamad A. Alsaud, Arwa E. Sasi, Sreethish Ali, Elrazi A. Hassan, Ola A. Iqbal, Fatima M. Nashwan, Abdulqadir J. Fahad, Jesin El Madhoun, Ihab Yassin, Mohamed Acta Biomed Original Investigations / Commentaries BACKGROUND: There is a scarcity of data regarding the effect of Type 2 diabetes mellitus (T2DM) and associated comorbidities on the clinical presentation and outcome of symptomatic patients with COVID-19 infection in comparison with non-diabetic patients. AIM OF THE STUDY: We described and compared the clinical presentation and radiological and hematological data of a cohort of symptomatic COVID19 positive T2DM diabetic patients (n = 59) versus another cohort of non-diabetic symptomatic COVID19 positive patients (n =244) diagnosed at the same time from January 2020 to May 2020. Associated comorbidities were assessed, and the Charlson Comorbidity Index was calculated. The outcomes including duration of hospitalization, duration of Intensive Care Unit (ICU) stay, duration of mechanical ventilation, and duration of O2 supplementation were assessed. RESULTS: Prevalence of T2DM in symptomatic COVID19 positive patients was 59/303 (=19.5%). Diabetic patients had higher prevalence of hypertension, chronic kidney disease (CKD) and cardiac dysfunction [coronary heart disease (CHD)], and congestive heart failure (CHF). Charlson Comorbidity score was significantly higher in the T2DM patients (2.4± 1.6) versus the non-diabetic patients (0.28 ± 0.8; p: < 0.001). Clinically and radiologically, T2DM patients had significantly higher percentage of pneumonia, severe pneumonia and ARDS versus the non-diabetic patients. Hematologically, diabetic patients had significantly higher C-reactive protein (CRP), higher absolute neutrophilic count (ANC) and lower counts of lymphocytes and eosinophils compared to non-diabetic patients. They had significantly higher systolic and diastolic blood pressures, longer duration of hospitalization, ICU stay, mechanical ventilation and oxygen therapy. CRP was correlated significantly with the duration of stay in the ICU and the duration for oxygen supplementation (r = 0.37 and 0.42 respectively; p: <0.01). CONCLUSIONS: T2DM patients showed higher inflammatory response to COVID 19 with higher absolute neutrophilic count (ANC) and CRP with lower lymphocytic and eosinophilic counts. Diabetic patients had more comorbidities and more aggressive course of the disease with higher rate of ICU admission and longer need for hospitalization and oxygen use. Mattioli 1885 2020 2020-09-07 /pmc/articles/PMC7716959/ /pubmed/32921708 http://dx.doi.org/10.23750/abm.v91i3.10214 Text en Copyright: © 2020 ACTA BIO MEDICA SOCIETY OF MEDICINE AND NATURAL SCIENCES OF PARMA http://creativecommons.org/licenses/by-nc-sa/4.0 This work is licensed under a Creative Commons Attribution 4.0 International License
spellingShingle Original Investigations / Commentaries
Soliman, Ashraf
Prabhakaran Nair, Arun
Al Masalamani, Muna S.
De Sanctis, Vincenzo
Abu Khattab, Mohamad A.
Alsaud, Arwa E.
Sasi, Sreethish
Ali, Elrazi A.
Hassan, Ola A.
Iqbal, Fatima M.
Nashwan, Abdulqadir J.
Fahad, Jesin
El Madhoun, Ihab
Yassin, Mohamed
Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study
title Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study
title_full Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study
title_fullStr Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study
title_full_unstemmed Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study
title_short Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study
title_sort prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with covid-19: a comparative study
topic Original Investigations / Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716959/
https://www.ncbi.nlm.nih.gov/pubmed/32921708
http://dx.doi.org/10.23750/abm.v91i3.10214
work_keys_str_mv AT solimanashraf prevalenceclinicalmanifestationsandbiochemicaldataoftype2diabetesmellitusversusnondiabeticsymptomaticpatientswithcovid19acomparativestudy
AT prabhakarannairarun prevalenceclinicalmanifestationsandbiochemicaldataoftype2diabetesmellitusversusnondiabeticsymptomaticpatientswithcovid19acomparativestudy
AT almasalamanimunas prevalenceclinicalmanifestationsandbiochemicaldataoftype2diabetesmellitusversusnondiabeticsymptomaticpatientswithcovid19acomparativestudy
AT desanctisvincenzo prevalenceclinicalmanifestationsandbiochemicaldataoftype2diabetesmellitusversusnondiabeticsymptomaticpatientswithcovid19acomparativestudy
AT abukhattabmohamada prevalenceclinicalmanifestationsandbiochemicaldataoftype2diabetesmellitusversusnondiabeticsymptomaticpatientswithcovid19acomparativestudy
AT alsaudarwae prevalenceclinicalmanifestationsandbiochemicaldataoftype2diabetesmellitusversusnondiabeticsymptomaticpatientswithcovid19acomparativestudy
AT sasisreethish prevalenceclinicalmanifestationsandbiochemicaldataoftype2diabetesmellitusversusnondiabeticsymptomaticpatientswithcovid19acomparativestudy
AT alielrazia prevalenceclinicalmanifestationsandbiochemicaldataoftype2diabetesmellitusversusnondiabeticsymptomaticpatientswithcovid19acomparativestudy
AT hassanolaa prevalenceclinicalmanifestationsandbiochemicaldataoftype2diabetesmellitusversusnondiabeticsymptomaticpatientswithcovid19acomparativestudy
AT iqbalfatimam prevalenceclinicalmanifestationsandbiochemicaldataoftype2diabetesmellitusversusnondiabeticsymptomaticpatientswithcovid19acomparativestudy
AT nashwanabdulqadirj prevalenceclinicalmanifestationsandbiochemicaldataoftype2diabetesmellitusversusnondiabeticsymptomaticpatientswithcovid19acomparativestudy
AT fahadjesin prevalenceclinicalmanifestationsandbiochemicaldataoftype2diabetesmellitusversusnondiabeticsymptomaticpatientswithcovid19acomparativestudy
AT elmadhounihab prevalenceclinicalmanifestationsandbiochemicaldataoftype2diabetesmellitusversusnondiabeticsymptomaticpatientswithcovid19acomparativestudy
AT yassinmohamed prevalenceclinicalmanifestationsandbiochemicaldataoftype2diabetesmellitusversusnondiabeticsymptomaticpatientswithcovid19acomparativestudy